Barclays Maintains Overweight on Medtronic, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Medtronic and raises the price target from $104 to $105.
August 22, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Medtronic and raises the price target from $104 to $105, indicating a positive outlook.
The Overweight rating suggests that Barclays expects Medtronic to outperform the market. The slight increase in the price target from $104 to $105 indicates a positive, albeit modest, outlook for the stock. This could lead to a short-term positive impact on MDT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100